Brent Sabatini Sells 1,562 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,562 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $9.15, for a total value of $14,292.30. Following the completion of the sale, the chief accounting officer now owns 28,189 shares of the company’s stock, valued at $257,929.35. The trade was a 5.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Vir Biotechnology Stock Performance

Shares of VIR opened at $9.65 on Friday. The company’s fifty day moving average is $9.13 and its 200 day moving average is $8.47. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45.

Institutional Trading of Vir Biotechnology

Large investors have recently made changes to their positions in the business. Blue Trust Inc. grew its position in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after acquiring an additional 2,351 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of Vir Biotechnology in the 3rd quarter valued at approximately $56,000. SBI Securities Co. Ltd. purchased a new position in shares of Vir Biotechnology in the 4th quarter worth approximately $60,000. PNC Financial Services Group Inc. increased its position in shares of Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,999 shares during the last quarter. Finally, KBC Group NV increased its position in shares of Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after purchasing an additional 5,177 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

VIR has been the subject of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. JPMorgan Chase & Co. increased their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a report on Thursday, January 9th. Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, January 31st. Finally, Barclays decreased their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.83.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).